{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:30:59Z","timestamp":1781555459337,"version":"3.54.5"},"reference-count":53,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vaccine.2023.04.041","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T04:04:01Z","timestamp":1681790641000},"page":"3422-3428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines"],"prefix":"10.1016","volume":"41","author":[{"given":"Alexis","family":"Pillsbury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0066-2218","authenticated-orcid":false,"given":"Lucy","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4675-0232","authenticated-orcid":false,"given":"Kristine","family":"Macartney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7595-9281","authenticated-orcid":false,"given":"Heather","family":"Gidding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.04.041_b0005","unstructured":"Australian Government Department of Health. Approved COVID-19 vaccines 2022 [March 24, 2022]. Available from: https:\/\/www.health.gov.au\/initiatives-and-programs\/covid-19-vaccines\/approved-vaccines."},{"key":"10.1016\/j.vaccine.2023.04.041_bib261","unstructured":"Australian Government Department of Health and Aged Care. Vaxzevria (AstraZeneca) vaccine and thrombosis with thrombocytopenia (TTS) 2023 [Available from: https:\/\/www.health.gov.au\/our-work\/covid-19-vaccines\/advice-for-providers\/clinical-guidance\/tts."},{"key":"10.1016\/j.vaccine.2023.04.041_b0010","unstructured":"Australian Government Department of Health Therapeutic Goods Administration. COVID-19 vaccine weekly safety report - 09-03-2023 2022 [Available from: https:\/\/www.tga.gov.au\/news\/covid-19-vaccine-safety-reports."},{"key":"10.1016\/j.vaccine.2023.04.041_b0015","unstructured":"Australian Government Department of Health. COVID-19 vaccine rollout update - 03 August 2022 2022 [Available from: https:\/\/www.health.gov.au\/sites\/default\/files\/documents\/2022\/08\/covid-19-vaccine-rollout-update-3-august-2022.pdf."},{"key":"10.1016\/j.vaccine.2023.04.041_b0020","unstructured":"World Health Organization. Adverse Events Following Immunization (AEFI) [March 24, 2022]. Available from: https:\/\/www.who.int\/teams\/regulation-prequalification\/regulation-and-safety\/pharmacovigilance\/health-professionals-info\/aefi."},{"issue":"4","key":"10.1016\/j.vaccine.2023.04.041_b0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10389-008-0201-1","article-title":"The public perception of the value of vaccines - the case of Switzerland","volume":"16","author":"Siegrist","year":"2008","journal-title":"Z Gesundh Wiss"},{"issue":"11","key":"10.1016\/j.vaccine.2023.04.041_b0030","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/INF.0b013e318149dfea","article-title":"Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions","volume":"26","author":"Siegrist","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2023.04.041_b0035","series-title":"How can we know how safe COVID-9 vaccines will be? Clinical Vaccinology Update (CVU) - December 2020; December 7, 2020","author":"Petousis-Harris","year":"2021"},{"issue":"19","key":"10.1016\/j.vaccine.2023.04.041_b0040","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.vaccine.2021.03.016","article-title":"The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety","volume":"39","author":"Black","year":"2021","journal-title":"Vaccine"},{"issue":"9707","key":"10.1016\/j.vaccine.2023.04.041_b0045","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines","volume":"374","author":"Black","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.04.041_b0050","unstructured":"VAC4EU. COVID-19 vaccine monitoring 2019 [March 25, 2022]. Available from: https:\/\/vac4eu.org\/covid-19-vaccine-monitoring\/."},{"key":"10.1016\/j.vaccine.2023.04.041_b0055","unstructured":"Law B, Sturkenboom M. Safety Platform for Emergency vACcines: D2.3 Priority List of Adverse Events of Special Interest: COVID-19. 2020."},{"issue":"22","key":"10.1016\/j.vaccine.2023.04.041_b0060","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.vaccine.2023.04.041_b0065","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2023.04.041_b0070","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1161\/STROKEAHA.116.013617","article-title":"Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought: A Retrospective Population-Based Study","volume":"47","author":"Devasagayam","year":"2016","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.vaccine.2023.04.041_b0075","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3201\/eid1509.081540","article-title":"Etiology of encephalitis in Australia, 1990\u20132007","volume":"15","author":"Huppatz","year":"2009","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2023.04.041_b0080","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaci.2008.10.049","article-title":"Anaphylaxis fatalities and admissions in Australia","volume":"123","author":"Liew","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"40","key":"10.1016\/j.vaccine.2023.04.041_b0085","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.1016\/j.vaccine.2021.07.059","article-title":"From program suspension to the pandemic: A qualitative examination of Australia's vaccine pharmacovigilance system over 10 years","volume":"39","author":"Phillips","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.041_b0090","unstructured":"Australian Bureau of Statistics. Table 51. Estimated Resident Population By Single Year of Age, New South Wales 2022 [Available from: https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/latest-release#data-download."},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.041_b0095","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/ije\/dyv322","article-title":"Probabilistic record linkage","volume":"45","author":"Sayers","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2023.04.041_b0100","unstructured":"Willame C, Dodd C, Gini R, Duran CE, Thomsen RM, Lei W, et al. Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (Version 1.1; September 21, 2020) 2021 [Available from: https:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=37274."},{"key":"10.1016\/j.vaccine.2023.04.041_b0105","unstructured":"Willame C, Dodd C, Gini R, Dur\u00e1n CE, Ehrenstein V, Thomsen RM, et al. Background rates of Adverse Events of Special Interest for monitoring of COVID-19 vaccines, an ACCESS study. D3-Draft Final Report. 2021 April 30, 2021."},{"key":"10.1016\/j.vaccine.2023.04.041_b0110","unstructured":"Melbourne Vaccine Education Centre. Thrombosis with thrombocytopenia syndrome (TTS) 2021 [Available from: https:\/\/mvec.mcri.edu.au\/references\/thrombosis-with-thrombocytopenia-syndrome\/."},{"issue":"4","key":"10.1016\/j.vaccine.2023.04.041_b0115","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.04.041_b0120","unstructured":"Australian Bureau of Statistics. Table 59. Estimated Resident Population By Single Year of Age, Australia 2022 [Available from: https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/latest-release#data-download."},{"key":"10.1016\/j.vaccine.2023.04.041_b0125","article-title":"Expected Rates of Select Adverse Events After Immunization for Coronavirus Disease 2019 Vaccine Safety Monitoring","author":"Abara","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.041_b0130","article-title":"Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.04.041_b0135","doi-asserted-by":"crossref","unstructured":"Nyberg F, Lindh M, Vanfleteren LEGW, Hammar N, Wettermark B, Sundstr\u00f6m J, et al. Adverse events of special interest for COVID-19 vaccines - background incidences vary by sex, age and time period and are affected by the pandemic. medRxiv. 2021:2021.10.04.21263507.","DOI":"10.1101\/2021.10.04.21263507"},{"issue":"28","key":"10.1016\/j.vaccine.2023.04.041_b0140","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1016\/j.vaccine.2021.05.016","article-title":"U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines","volume":"39","author":"Gubernot","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.041_b0145","unstructured":"The World Bank. Death rate, crude (per 1,000 people) 2022 [Available from: https:\/\/data.worldbank.org\/indicator\/SP.DYN.CDRT.IN?end=2018&most_recent_year_desc=true&start=2000."},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.041_b0150","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vaccine.2022.11.031","article-title":"Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study","volume":"41","author":"Willame","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.041_b0155","doi-asserted-by":"crossref","unstructured":"Nasreen S, Calzavara A, Buchan SA, Thampi N, Johnson C, Wilson SE, et al. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance. medRxiv. 2022:2022.01.12.22269169.","DOI":"10.1101\/2022.01.12.22269169"},{"key":"10.1016\/j.vaccine.2023.04.041_b0160","unstructured":"Parliament of the Commonwealth of Australia. Walking the allergy tightrope: addressing the rise of allergies and anaphylaxis in Australia. Canberra: Commonwealth of Australia; 2020."},{"issue":"2","key":"10.1016\/j.vaccine.2023.04.041_b0165","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jaci.2015.05.009","article-title":"Time trends in Australian hospital anaphylaxis admissions in 1998\u20131999 to 2011\u20132012","volume":"136","author":"Mullins","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2023.04.041_b0170","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/cea.12748","article-title":"Increases in anaphylaxis fatalities in Australia from 1997 to 2013","volume":"46","author":"Mullins","year":"2016","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.vaccine.2023.04.041_b0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"issue":"10","key":"10.1016\/j.vaccine.2023.04.041_b0180","doi-asserted-by":"crossref","first-page":"574","DOI":"10.5694\/mja12.10534","article-title":"Guillain-Barr\u00e9 syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self-controlled case series","volume":"197","author":"Crawford","year":"2012","journal-title":"Med J Aust"},{"issue":"2","key":"10.1016\/j.vaccine.2023.04.041_b0185","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.vaccine.2022.11.003","article-title":"Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019\u20132020","volume":"41","author":"Moll","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.041_b0190","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/CLEP.S199839","article-title":"Guillain-Barr\u00e9 syndrome in Denmark: validation of diagnostic codes and a population-based nationwide study of the incidence in a 30-year period","volume":"11","author":"Levison","year":"2019","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2023.04.041_b0195","article-title":"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study","volume":"373","author":"Potteg\u00e5rd","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.04.041_b0200","unstructured":"European Medicines Agency. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets 2021 [Available from: https:\/\/www.ema.europa.eu\/en\/news\/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood."},{"issue":"5","key":"10.1016\/j.vaccine.2023.04.041_b0205","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/pds.5419","article-title":"Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries","volume":"31","author":"Burn","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.041_b0210","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/STROKEAHA.120.031026","article-title":"Cerebral Venous Thrombosis: Finnish Nationwide Trends","volume":"52","author":"Ruuskanen","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.vaccine.2023.04.041_b0215","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/VHRM.S197732","article-title":"Splanchnic Vein Thrombosis: Current Perspectives","volume":"15","author":"Valeriani","year":"2019","journal-title":"Vasc Health Risk Manag"},{"issue":"4","key":"10.1016\/j.vaccine.2023.04.041_b0220","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1160\/TH16-10-0781","article-title":"Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome","volume":"117","author":"Ageno","year":"2017","journal-title":"Thromb Haemost"},{"issue":"10342","key":"10.1016\/j.vaccine.2023.04.041_b0225","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(22)00842-X","article-title":"COVID-19 mRNA vaccination and myocarditis or pericarditis","volume":"399","author":"Husby","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.04.041_b0230","doi-asserted-by":"crossref","unstructured":"Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risk of myocarditis following sequential COVID-19 vaccinations by age and sex. medRxiv. 2021:2021.12.23.21268276.","DOI":"10.1101\/2021.12.23.21268276"},{"issue":"10","key":"10.1016\/j.vaccine.2023.04.041_b0235","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/jamacardio.2021.2833","article-title":"Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military","volume":"6","author":"Montgomery","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"23","key":"10.1016\/j.vaccine.2023.04.041_b0240","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after Covid-19 Vaccination in a Large Health Care Organization","volume":"385","author":"Witberg","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.04.041_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2022.05.048","article-title":"Myocarditis and\/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines","author":"Abraham","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.041_b0250","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12874-020-01108-6","article-title":"The effects of different lookback periods on the sociodemographic structure of the study population and on the estimation of incidence rates: analyses with German claims data","volume":"20","author":"Epping","year":"2020","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.vaccine.2023.04.041_b0255","unstructured":"Australian Bureau of Statistics (ABS). Regional population by age and sex 2022 [Available from: https:\/\/www.abs.gov.au\/statistics\/people\/population\/regional-population-age-and-sex\/latest-release."},{"key":"10.1016\/j.vaccine.2023.04.041_b0260","unstructured":"Global Vaccine Data Network (GVDN). Global Vaccine Data Network 2023 [Available from: https:\/\/www.globalvaccinedatanetwork.org\/."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:26:31Z","timestamp":1759404391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23004413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":53,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0264410X23004413"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.041","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}